BioCentury | Jun 13, 2005
Company News

Hemosol board of directors update

Hemosol Corp. (TSE:HML; HMSL), Mississauga, Ontario Business: Hematology Appointed: Paul Walker and Edward McCormack, a director, as chairman; former chairman Edward Rygiel will remain a director WIR Staff...
BioCentury | Apr 11, 2005
Company News

Hemosol, Biomedical Frontiers Inc. deal

...overload and diabetic complications. Biomedical’s iron-binding compounds are produced by chemically attaching deferoxamine to polymers. Hemosol Corp....
BioCentury | Jan 10, 2005
Company News

Vasogen management update

...Searle Division; Michael Shannon as VP of medical affairs, formerly VP of medical sciences at Hemosol Corp....
BioCentury | Oct 4, 2004
Company News

Akzo Nobel NV, Hemosol deal

...retinal vessel thrombosis to prevent thromboembolic phenomena. Akzo Nobel NV (Euronext:AKZ; AKZOY), Arnhem, the Netherlands Hemosol Corp....
BioCentury | Aug 16, 2004
Company News

Hemosol board of directors update

Hemosol Corp. (TSE:HML; HMSL), Toronto, Ontario Business: Hematology Appointed: Edward Lane, former CFO of the Canadian Red Cross; he replaces George Masters, who departed WIR Staff Hematology...
BioCentury | May 10, 2004
Company News

Hemosol, MDS deal

...in cash and allow MDS to benefit from HML's unused tax assets. Under the deal, Hemosol...
...to purchase Hemosol Inc. shares, MDS also received warrants to purchase 5.5 million shares of Hemosol Corp....
...MDS owns 11.7% of Hemosol Corp., which could increase to 22% if it exercises the warrants. Hemosol Corp....
BioCentury | Dec 8, 2003
Company News

Hemosol Inc., Prometic deal

...also will pay PLI about $16.5 million in license fees over four years, plus royalties. Hemosol...
BioCentury | Aug 25, 2003
Clinical News

Hemolink hemoglobin raffimer: Phase II

...myocardial infarctions in the Hemolink group compared to the control group (see BioCentury, March 17). Hemosol...
BioCentury | Jun 16, 2003
Clinical News

Hemolink: Phase II

...the U.K. had been put on hold after the DSMB analysis (see BioCentury, March 17). Hemosol...
BioCentury | May 5, 2003
Finance

Restructuring watch

...of its acquisition by Inflazyme (TSE:IZP) (see BioCentury, April 14). $13.0 1.1 $11.4 1/31 4/7/2003 Hemosol...
Items per page:
1 - 10 of 107
BioCentury | Jun 13, 2005
Company News

Hemosol board of directors update

Hemosol Corp. (TSE:HML; HMSL), Mississauga, Ontario Business: Hematology Appointed: Paul Walker and Edward McCormack, a director, as chairman; former chairman Edward Rygiel will remain a director WIR Staff...
BioCentury | Apr 11, 2005
Company News

Hemosol, Biomedical Frontiers Inc. deal

...overload and diabetic complications. Biomedical’s iron-binding compounds are produced by chemically attaching deferoxamine to polymers. Hemosol Corp....
BioCentury | Jan 10, 2005
Company News

Vasogen management update

...Searle Division; Michael Shannon as VP of medical affairs, formerly VP of medical sciences at Hemosol Corp....
BioCentury | Oct 4, 2004
Company News

Akzo Nobel NV, Hemosol deal

...retinal vessel thrombosis to prevent thromboembolic phenomena. Akzo Nobel NV (Euronext:AKZ; AKZOY), Arnhem, the Netherlands Hemosol Corp....
BioCentury | Aug 16, 2004
Company News

Hemosol board of directors update

Hemosol Corp. (TSE:HML; HMSL), Toronto, Ontario Business: Hematology Appointed: Edward Lane, former CFO of the Canadian Red Cross; he replaces George Masters, who departed WIR Staff Hematology...
BioCentury | May 10, 2004
Company News

Hemosol, MDS deal

...in cash and allow MDS to benefit from HML's unused tax assets. Under the deal, Hemosol...
...to purchase Hemosol Inc. shares, MDS also received warrants to purchase 5.5 million shares of Hemosol Corp....
...MDS owns 11.7% of Hemosol Corp., which could increase to 22% if it exercises the warrants. Hemosol Corp....
BioCentury | Dec 8, 2003
Company News

Hemosol Inc., Prometic deal

...also will pay PLI about $16.5 million in license fees over four years, plus royalties. Hemosol...
BioCentury | Aug 25, 2003
Clinical News

Hemolink hemoglobin raffimer: Phase II

...myocardial infarctions in the Hemolink group compared to the control group (see BioCentury, March 17). Hemosol...
BioCentury | Jun 16, 2003
Clinical News

Hemolink: Phase II

...the U.K. had been put on hold after the DSMB analysis (see BioCentury, March 17). Hemosol...
BioCentury | May 5, 2003
Finance

Restructuring watch

...of its acquisition by Inflazyme (TSE:IZP) (see BioCentury, April 14). $13.0 1.1 $11.4 1/31 4/7/2003 Hemosol...
Items per page:
1 - 10 of 107